Organization | Metabolic Technologies

Metabolic Technologies Report issue

For profit Phase 1

Founded: Ames IA United States (1990)

Status: No NME R&D (1990)

Organization Overview

First Clinical Trial

2008

NCT00874575

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Metabolic Technologies Inc. | Metabolic Technologies, LLC

Active Ingredients

Drugs in Phase 1 Trials (5)

2-hoba (4 trials)

adenosine 5'-triphosphate disodium salt (2 trials)

beta-hydroxyisovaleric acid (9 trials)

calcium beta-hydroxy-beta-methylbutyrate (1 trial)

vitamin d3 (3 trials)

Drugs in Other Trials (6)

bacillus coagulans (1 trial)

bovine albumin (1 trial)

hydroxymethylbutyrate (2 trials)

triphosphoric acid adenosine ester (2 trials)

vitamin d (1 trial)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Sarcopenia (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 19
# of Trial APIs: 11